Photo from wikipedia
ATOS was a 12-month prospective observational study in 18 countries outside US and Western Europe in insulin-naive adults with T2DM, uncontrolled (HbA1c >7-≤11%) on ≥1 oral anti-hyperglycemic drug. This subgroup… Click to show full abstract
ATOS was a 12-month prospective observational study in 18 countries outside US and Western Europe in insulin-naive adults with T2DM, uncontrolled (HbA1c >7-≤11%) on ≥1 oral anti-hyperglycemic drug. This subgroup analysis of ATOS compared the effectiveness and safety of Gla-300 in older (≥70 years [Y]; N=514) and younger ( Disclosure G. R. Galstyan: None. A. Tirosh: Advisory Panel; Self; AstraZeneca, Eli Lilly and Company, Novo Nordisk, Sanofi, Consultant; Self; DreaMed Diabetes, Ltd. H. Vargas-uricoechea: Advisory Panel; Spouse/Partner; Sanofi. M. N. Mabunay: Employee; Self; Sanofi, Stock/Shareholder; Self; Sanofi. M. Coudert: Employee; Self; Sanofi. V. Pilorget: Employee; Self; Sanofi. N. Khan: None. Funding Sanofi
Journal Title: Diabetes
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!